Browse > Article
http://dx.doi.org/10.7314/APJCP.2014.15.14.5535

Analysis of Indoleamine 2-3 Dioxygenase (IDO) and EGFR Co-expression in Breast Cancer Tissue by Immunohistochemistry  

Bi, Wei-Wei (Department of Biological Engineering College of Pharmacy Jilin University)
Zhang, Wei-Hua (Siping Hospital of China Medical University)
Yin, Gui-Hua (Siping Hospital of China Medical University)
Luo, Hong (Siping Hospital of China Medical University)
Wang, Shou-Qin (Siping Hospital of China Medical University)
Wang, Hongran (Department of Molecular and Cellular Biology, Baylor College of Medicine)
Li, Chao (TuoHua Biological Technology Company)
Yan, Wei-Qun (Department of Biological Engineering College of Pharmacy Jilin University)
Nie, De-Zhi (TuoHua Biological Technology Company)
Publication Information
Asian Pacific Journal of Cancer Prevention / v.15, no.14, 2014 , pp. 5535-5538 More about this Journal
Abstract
Background: To determine the amount of co-expression of IDO and EGFR in breast cancer patients. Materials and Methods:In order to obtain the distribution of co-expression of IDO and EGFR in breast cancer, we tested 110 breast cancer paraffin tissue blocks with immunohistochemical methods. Then we investigated the relationship between the diagnostic and pathologic characteristics (tumor size, lymph node status, histologic grade, the gene expression of ER, PR, HER2, p53, Ki67 and PCNA) with the situation of co-expression of IDO and EGFR by reviewing the medical records of 32 breast cancer patients. Results: Among 110 breast cancers, 32 cases demonstrated IDO and EGFR co-expression (29.1%), IDO and EGFR synchronous co-expression being found in 19.1% and asynchronous in 10.0%. Conclusions: IDO and EGFR were co-expressed in breast cancer, including synchronous and asynchronous co-expression. The results suggest that considering IDO and EGFR as two indicators for breast cancer treatment or prognosis analysis provides a potential option of individual treatment for the portion of breast cancer patients with co-expression of IDO and EGFR.
Keywords
EGFR; IDO; co-expression; breast cancer;
Citations & Related Records
Times Cited By KSCI : 4  (Citation Analysis)
연도 인용수 순위
1 Tan DS, Marchio C, Jones RL, et al (2008). Triple negative breast cancer: molecular profiling and prognostic impact in adjuvant anthracycline-treated patients. Breast Cancer Res Tr, 111, 27-44.   DOI   ScienceOn
2 Tong L, Yang XX, Liu MF, et al (2012). Mutational analysis of key EGFR pathway genes in Chinese breast cancer patients. Asian Pac J Cancer Prev, 13, 5599-603.   과학기술학회마을   DOI   ScienceOn
3 Van der Loos CM, Das PK, Houthoff HJ (1987). An immunoenzyme triple-staining method using both polyclonal and monoclonal antibodies from the samespecies. Application of combined direct, indirect, and avidin-biotin complex (ABC) technique. J Histochem Cytochem, 35, 1199-204.   DOI
4 Van Noorden S, Stuart MC, Cheung A, et al (1986). Localization of human pituitary hormones by multiple immunoenzyme staining procedures using monoclonal andpolyclonal antibodies. J Histochem Cytochem, 34, 287-92.   DOI
5 Arteaga C (2003). Targeting HER1/EGFR: a molecular approach to cancer therapy. Semin Oncol, 30, 3-14.   DOI
6 Hu Q, Luo Z , Xu T, et al (2014). FOXA1: a promising prognostic marker in breast cancer. Asian Pac J Cancer Prev, 15, 11-6.   과학기술학회마을   DOI
7 Abediankenari S, Jeivad F (2013). Epidermal growth factor receptor gene polymorphisms and gastric cancer in Iran. Asian Pac J Cancer Prev, 14, 3187-90.   과학기술학회마을   DOI
8 Brandacher G , Perathoner A, Ladurner R, et al (2006). Prognostic value of indoleamine 2, 3-dioxygenase expression in colorectal cancer: effect on tumor-infiltrating T cells. Clin Cancer Res, 12, 1144-51.   DOI
9 Cheang MC, Voduc D, Bajdik C, et al (2008). Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype. Clin Cancer Res, 14, 1368-76.   DOI   ScienceOn
10 Ino K, Yoshida N, Kajiyama H, et al (2006). Indoleamine 2, 3-dioxygenase is a novel prognostic indicator for endometrial cancer. Br J Cancer, 95, 1555-61.   DOI
11 Kim H, Choi DH, Park W, et al (2013). Prognostic factors for survivals from first relapse in breast cancer patients: analysis of deceased patients. Radiat Oncol J, 31, 222-7.   DOI
12 Mansfield AS, Heikkila PS, Vaara AT, et al (2009). Simultaneous Foxp3 and IDO expression is associated with sentinel lymph node metastases in breast cancer. BMC Cancer, 15, 231.
13 Okamoto H, Fujishima F, Nakamura Y, et al (2013). Significance of CD133 expression in esophageal squamous cell carcinoma. World J Surg Oncol, 11, 51.   DOI
14 Rakha EA, Elsheikh SE, Aleskandarany MA, et al (2009). Triplenegative breast cancer: distinguishing between basal and nonbasal subtypes. Clin Cancer Res, 15, 2302-10.   DOI   ScienceOn